| 1. |
- Brew, Bronwyn K., et al.
(författare)
-
Academic achievement of adolescents with asthma or atopic disease
- 2019
-
Ingår i: Clinical and Experimental Allergy. - : Wiley. - 0954-7894 .- 1365-2222. ; 49:6, s. 892-899
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundOver a fifth of children and adolescents suffer with asthma or atopic disease. It is unclear whether asthma impacts academic performance in children and adolescents, and little is known about the association of eczema, food allergy or hayfever and academic performance.ObjectiveTo examine whether asthma, eczema, food allergy or hayfever impacts on adolescent academic performance and to assess the role of unmeasured confounding.MethodsThis study used the Childhood and Adolescent Twin Study of Sweden cohort born 1992‐1998. At age 9‐12 years, parents reported on their child's ever or current asthma, eczema, food allergy and hayfever status (n = 10 963). At age 15, linked national patient and medication register information was used to create current and ever asthma definitions including severe and uncontrolled asthma for the same children. Academic outcomes in Grade 9 (age 15‐16 years) included: eligibility for high school (Grades 10‐12), and total mark of the best 16 subject units, retrieved from the Grade 9 academic register. Whole cohort analyses adjusted for known covariates were performed, and co‐twin control analyses to assess unmeasured confounders.ResultsThere were no associations found for asthma or food allergy at 9‐12 years and academic outcomes in adolescence. In addition, at age 15, there were no statistically significant associations with current, ever, severe or uncontrolled asthma and academic outcomes. Eczema and hayfever at age 9‐12 years were found to be positively associated with academic outcomes; however, co‐twin control analyses did not support these findings, suggesting the main analyses may be subject to unmeasured confounding.Conclusion and clinical relevanceHaving asthma or an atopic disease during childhood or adolescence does not negatively impact on academic performance. This information can be used by clinicians when talking with children and parents about the implications of living with asthma or atopic disease.
|
|
| 2. |
- Roshanbin, Sahar, 1984-, et al.
(författare)
-
In vivo imaging of alpha-synuclein with antibody-based PET
- 2022
-
Ingår i: Neuropharmacology. - : Elsevier. - 0028-3908 .- 1873-7064. ; 208
-
Tidskriftsartikel (refereegranskat)abstract
- The protein alpha-synuclein (alpha SYN) plays a central role in synucleinopathies such as Parkinsons's disease (PD) and multiple system atrophy (MSA). Presently, there are no selective alpha SYN positron emission tomography (PET) radioligands that do not also show affinity to amyloid-beta (A beta). We have previously shown that radiolabeled antibodies, engineered to enter the brain via the transferrin receptor (TfR), is a promising approach for PET imaging of intrabrain targets. In this study, we used this strategy to visualize alpha SYN in the living mouse brain. Five bispecific antibodies, binding to both the murine TfR and alpha SYN were generated and radiolabeled with iodine-125 or iodine-124. All bispecific antibodies bound to alpha SYN and mTfR before and after radiolabelling in an ELISA assay, and bound to brain sections prepared from alpha SYN overexpressing mice as well as human PD- and MSA subjects, but not control tissues in autoradiography. Brain concentrations of the bispecific antibodies were be-tween 26 and 63 times higher than the unmodified IgG format 2 h post-injection, corresponding to about 1.5% of the injected dose per gram brain tissue. Additionally, intrastriatal alpha SYN fibrils were visualized with PET in an alpha SYN deposition mouse model with one of the bispecific antibodies, [I-124]RmAbSynO2-scFv8D3. However, PET images acquired in alpha SYN transgenic mice with verified brain pathology injected with [I-124]RmAbSynO2-scFv8D3 and [I-124]RmAb48-scFv8D3 showed no increase in antibody retention compared to WT mice. Despite successful imaging of deposited extracellular alpha SYN using a brain-penetrating antibody-based radioligand with no cross-specificity towards A beta, this proof-of-concept study demonstrates challenges in imaging intracellular alpha SYN inclusions present in synucleinopathies.
|
|
